Axsome Therapeutics (AXSM) Work In Process (2022 - 2026)

Axsome Therapeutics (AXSM) has 5 years of Work In Process data on file, last reported at $15.5 million in Q1 2026.

• For the quarter ending Q1 2026, Work In Process rose 127.41% year-over-year to $15.5 million; the trailing twelve-month figure through Mar 2026 stood at $15.5 million (up 127.41% YoY), and the FY2025 full-year result was $17.8 million, up 130.95% from the prior year.
• Work In Process slipped to $15.5 million in Q1 2026, from $17.8 million in the prior quarter.
• In the past five years, Work In Process ranged from a high of $17.8 million in Q4 2025 to a low of $6.8 million in Q1 2025.
• A 5-year average of $11.0 million and a median of $10.5 million in 2024 frame the typical range for Work In Process.
• Peak annual rise in Work In Process reached 130.95% in 2025, while the deepest fall reached 37.64% in 2025.
• Tracing AXSM's Work In Process over 5 years: stood at $14.0 million in 2022, then fell by 26.34% to $10.3 million in 2023, then slipped by 24.92% to $7.7 million in 2024, then soared by 130.95% to $17.8 million in 2025, then slipped by 13.34% to $15.5 million in 2026.
• Business Quant data shows AXSM's Work In Process at $15.5 million in Q1 2026, $17.8 million in Q4 2025, and $12.9 million in Q3 2025.